Brooklyn ImmunoTherapeutics Inc

BTX 4 | $4.102 -93.91%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (2.5% 3d) (0.0% 7d) (768.24% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 241,303,181
https://brooklynitx.com
Sec Filling | Patents | 2018 employees

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

cancer t-cell msa ceiling

add to watch list Paper trade email alert is off

KonaRed Corp

KRED | $0.0001 0.0% 940K

Information

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (9279.31% volume)
Earnings Calendar:
Market Cap: $ 22,797

Sec Filling | Patents | 11 employees

konared is a powerful hawaiian superfruit! it is rich, fully-ripened coffee fruit from kona, hawaii that is bursting with extraordinary nutrients, carefully preserved and crafted into a daily elixir. it is the fruit that surrounds, shelters and nourishes the coffee seed (bean). created by nature, coffee fruit stores unique antioxidants and nutrients to protect its seeds from the tropical sun and other environmental stress. these superior antioxidants are known to help with neutralizing free radicals and repairing cell damage! konared - wellness you can feel!

t-cell

add to watch list Paper trade email alert is off

Eterna Therapeutics Inc

ERNA | $2.16 0.47% 0.46% 3.7K

Information

(0.0% 1d) (-2.3% 1m) (-31.9% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (8.64% volume)
Earnings Calendar:
Market Cap: $ 11,686,315

Sec Filling | Patents | 2018 employees

brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.

t-cell

add to watch list Paper trade email alert is off

Resonate Blends, Inc.

KOAN | $0.0395 -35.11% 43K

Information

(0.0% 1d) (-3.9% 1m) (6.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4259000.0% volume)
Earnings Calendar:
Market Cap: $ 3,799,073

Sec Filling | Patents | 2018 employees

resonate blends, inc., a cannabis holding company, provides cannabis-based products. it also operates an online mobile marketing platform that provides various offers, discounts, and alerts and events schedules, such as happy hours, trivia night, and other campaigns, as well as events, deals, and messages on their cell phone via sms messaging to gyms, bars, boutiques, dentists, salons, restaurants, investor relations firms, real estate agents, and digital marketing agencies. the company was formerly known as textmunication holdings, inc. and changed its name to resonate blends, inc. in december 2019. resonate blends, inc. is based in calabasas, california.

t-cell

add to watch list Paper trade email alert is off